Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pleural Effusion II: Symptoms and Management01:28

Pleural Effusion II: Symptoms and Management

Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cystic Fibrosis Transmembrane Conductance Regulator Mutations and Potential Associations With Increased Rates of Pulmonary Infections Among Patients from the US Bronchiectasis and NTM Research Registry.

Chest·2026
Same author

Time to Reconsider Mucoactive Agents for Airway Clearance.

The New England journal of medicine·2025
Same author

Five-Year Outcomes among U.S. Bronchiectasis and NTM Research Registry Patients.

American journal of respiratory and critical care medicine·2024
Same author

Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations.

The Lancet. Respiratory medicine·2021
Same author

Association between Cardiorespiratory Fitness and Bronchiectasis at CT: A Long-term Population-based Study of Healthy Young Adults Aged 18-30 Years in the CARDIA Study.

Radiology·2021
Same author

Pseudomonas aeruginosa associated with severity of non-cystic fibrosis bronchiectasis measured by the modified bronchiectasis severity score (BSI) and the FACED: The US bronchiectasis and NTM Research Registry (BRR) study.

Respiratory medicine·2021

Related Experiment Videos

Bronchiectasis, part 2: Management.

Meeta Prasad1, Gregory Tino

  • 1Division of Pulmonary, Allergy, and Critical Ccare Medicine of the University of Pennsylvania Health System, Philadelphia. Dr. Prasad is a postgraduate fellow, and Dr. Tino is associate professor of medicine and chief, pulmonary clinical service, Hospital of the University of Pennsylvania.

The Journal of Respiratory Diseases
|January 5, 2010
PubMed
Summary
This summary is machine-generated.

Systemic antibiotics manage bronchiectasis exacerbations, targeting key bacteria. Long-term macrolide therapy and airway clearance may reduce exacerbations and sputum.

Related Experiment Videos

Area of Science:

  • Pulmonology
  • Infectious Diseases

Background:

  • Acute exacerbations are a primary concern in bronchiectasis management.
  • Effective treatment strategies are crucial for improving patient outcomes.

Purpose of the Study:

  • To outline current best practices for managing acute exacerbations of bronchiectasis.
  • To discuss antibiotic selection, duration, and emerging therapies.

Main Methods:

  • Review of current literature on bronchiectasis exacerbation management.
  • Analysis of antibiotic efficacy against common pathogens like Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, and Pseudomonas species.
  • Evaluation of adjunctive therapies including long-term macrolides, inhaled antibiotics, and airway clearance techniques.

Main Results:

  • Systemic antibiotics are the cornerstone of treatment, requiring broad-spectrum coverage.
  • Prolonged antibiotic courses (often >3 weeks) are generally recommended.
  • Long-term, low-dose macrolide therapy shows promise in reducing exacerbation frequency and sputum production.
  • Airway clearance strategies are beneficial, particularly in patients with cystic fibrosis.
  • Surgical resection is an option for localized, refractory disease.

Conclusions:

  • Antibiotic choice and duration are critical in managing bronchiectasis exacerbations.
  • Adjuvant therapies like macrolides and airway clearance can significantly improve patient management.
  • Personalized treatment approaches, including considering surgical options, are important for refractory cases.